title: Comparison of initial intraocular pressure response with topical beta-adrenergic antagonists and prostaglandin analogues in African American and white individuals in the Ocular Hypertension Treatment Study.
abstract: OBJECTIVE
  To compare the intraocular pressure (IOP) responses of self-identified African American and white participants in the Ocular Hypertension Treatment Study to therapeutic trials of topical, nonselective beta-adrenergic antagonists or prostaglandin analogues.
  
  
  METHODS
  Multivariate models that adjusted for baseline IOP and corneal thickness were used to estimate IOP response by race. Participants included 536 who were prescribed topical beta-adrenergic antagonists and 191 who were prescribed prostaglandin analogues, 25% of whom were African American.
  
  
  METHODS
  Intraocular pressure response in the ipsilateral eye after 4 to 6 weeks of a therapeutic trial.
  
  
  RESULTS
  Intraocular pressure response to nonselective beta-adrenergic antagonists did not differ between African American and white participants. Intraocular pressure response to prostaglandin analogues was slightly greater in African American participants, but this difference was not statistically significant. With both classes of medication, greater IOP reduction was associated with higher baseline IOP and thinner central corneal measurement.
  
  
  CONCLUSIONS
  We found no statistically significant differences in IOP response to topical, nonselective beta-adrenergic antagonists or prostaglandin analogues between self-identified African American and white individuals. Application to Clinical Practice Studies of IOP response to medication should statistically adjust for baseline IOP and central corneal thickness. Clinicians should consider factors other than ethnicity when choosing an ocular hypotensive medication for a patient.
  
  
  BACKGROUND
  clinicaltrials.gov Identifier: NCT00000125.
authors.affiliation: Devers Eye Institute/Discoveries in Sight, Legacy Health System, Portland, Ore, USA.
authors.forename: Steven L
authors.initials: SL
authors.lastname: Mansberger
authors.forename: Bret A
authors.initials: BA
authors.lastname: Hughes
authors.forename: Mae O
authors.initials: MO
authors.lastname: Gordon
authors.forename: Steven D
authors.initials: SD
authors.lastname: Spaner
authors.forename: Julia A
authors.initials: JA
authors.lastname: Beiser
authors.forename: George A
authors.initials: GA
authors.lastname: Cioffi
authors.forename: Michael A
authors.initials: MA
authors.lastname: Kass
mesh_terms: D000287:Administration, Topical; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage*; D000328:Adult; D001741:Black or African American; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005902:Glaucoma, Open-Angle / Q000208:ethnology / Q000517:prevention & control; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy* / Q000208:ethnology*; D009883:Ophthalmic Solutions / Q000008:administration & dosage; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage*; D014065:Tonometry, Ocular; D044465:White People
chemical_list: D000319:Adrenergic beta-Antagonists; D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic